Neurotechnology Startups funded by Y Combinator (YC) 2026

We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding. 

Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.

Craniometrix has raised over $21 million to help make dementia suck less. Dementia is tough – but it can be easier. Turns out, if you give families the right non-clinical coaching and support, you can avoid 30% of hospitalizations for these patients. And Medicare has recently started paying for that coaching. We launched our care navigation service for dementia patients in July of 2025, hit $4M of ARR, and just raised a $15M Series A. We leverage AI to provide best-in-class care, alleviating the burden on providers. Come help us build!

We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy.

Non-invasive brain stimulation is a widely-utilized, FDA cleared treatment used for patients diagnosed with depression, but is limited to a hospital setting due to the cost of the device, and complexity of treatment application. Our proprietary brain stimulation device allows patients to be treated directly from their home, with the same efficacy, and at a lower cost of treatment. Currently in FDA pivotal phase for Major Depressive Disorder, and Pilot phase for Alzheimer's and Parkinson diseases.

We aren’t building AI to replace "knowledge work” that requires neither, but to bolster the working human intellect which has never failed to discover new paths to prosperity. For all their success, mainstream approaches to AI have fundamental limitations preventing them from solving critical classes of problems. We are building a new AI architecture from first principles to break from these limitations. The status quo has ossified around the supervised, brute-force pretraining paradigm. These systems do not, and cannot, handle the essential skills of continual learning, goal discovery, novel planning, and the creation of new knowledge. These limitations are not trivial. Our national prosperity depends directly on overcoming these limitations, because the essential skills underlie the skilled trades. From electricians to machinists to nurses, apprentice tradespeople in all of these fields learn “skilled improvisation” where every solution is novel, and even the goal must be discovered. Prosperity demands the precise capabilities where status quo AI is structurally weak. Worse, these limitations will not be overcome with more compute or training data. They are inescapable consequences of the underlying technologies of supervised learning, neural networks, transformers, backprop, and gradient descent. Progress requires independence from them. We are building a new AI architecture by reverse-engineering the system that got us this far: the human brain. By triangulating between neuroscience, cognitive science, and the evolutionary elaboration of brains, we have identified the brain’s algorithms to (a) continually learn a causal world model (b) select goals to both achieve and learn to achieve more (c) plan to reach novel goals, and (d) creatively produce new knowledge. Join us in building intelligence with ingenuity to bolster the skilled trades.

BrainKey is an AI-driven digital healthcare company with a mission to create a world free from dementia.

Nectome is a neuroscience startup that aims to preserve the brain and keep all its memories intact. The company is building the next generation of tools to preserve the connectome. The connectome is all the connections called synapses between neurons in the brain. Researchers from the company is now learning to manipulate individual memories, building advanced brain prosthetics, and reverse-engineering the brain.

BIOS Health was previously called Cambridge Bio-Augmentation Systems (CBAS) and focused on prosthetic neural interfaces as a first market. Now we use

Acquired by Penumbra (NYSE:PEN).

At Rain Neuromorphics, we envision a future where every device possesses a dynamic and continuously learning AI brain. Neural Networks are the most powerful engines behind today's AI, but simulations require massive amounts of power and time to learn all of the synaptic connections. As opposed to a simulation, our neuromorphic hardware is a physical artificial neural network, composed of spiking neurons and physical synapses. We combine unique electroceramic materials, nanofabrication techniques, and biologically plausible models of learning to create the Memristive Nanowire Neural Network (MN3), a new type of AI chip. The MN3 can possess over ten million spiking neurons per square centimeter, and uses far less power than conventional GPUs and CPUs.